X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, Sanofi has exercised its option for a second target as part of the companies' research collaboration to develop in vivo CRISPR-based therapeutics using Scribe’s engineered CRISPR technologies.
Lead Product(s): CRISPR-based Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $1,240.0 million Upfront Cash: $40.0 million
Deal Type: Expanded Collaboration January 03, 2024
Details:
Under the collaboration, Sanofi receives an exclusive license to use Scribe’s CRISPR X-Editing (XE) genome editing technologies for the development of in vivo NK-cell therapies, including sickle cell disease.
Lead Product(s): Ex-vivo NK Cell Therapy
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $1,240.0 million Upfront Cash: $40.0 million
Deal Type: Expanded Collaboration July 17, 2023
Details:
Under the collaboration, Prevail gets exclusive rights to Scribe’s CRISPR X-Editing (XE) technologies for the development of in vivo therapies directed to specified genetic targets known to cause serious neurological and neuromuscular diseases.
Lead Product(s): CRISPR-based Genetic Medicine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Prevail Therapeutics
Deal Size: $1,575.0 million Upfront Cash: $75.0 million
Deal Type: Collaboration May 16, 2023
Details:
The agreement grants Sanofi non-exclusive rights to Scribe’s proprietary CRISPR platform of wholly owned enzymes to create ex vivo NK cell therapies for multiple oncology targets.
Lead Product(s): NK Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sanofi
Deal Size: $1,025.0 million Upfront Cash: $25.0 million
Deal Type: Collaboration September 27, 2022
Details:
The expanded collaboration further validates Scribe’s position as a leading organization driving the development of novel CRISPR-based therapeutics that treat the underlying cause of disease.
Lead Product(s): CRISPR-based Therapeutic
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Biogen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration May 02, 2022
Details:
The capital will be used to further develop Scribe’s suite of custom gene editing and delivery technologies, as well as to advance a pipeline of therapeutics for neurodegeneration and additional diseases with high unmet need.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Avoro Ventures
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 31, 2021
Details:
Under the terms of the collaboration, Scribe will work with Biogen to create therapeutics for genetically-driven ALS, with an option to pursue an additional neurological disease target with high, unmet need.
Lead Product(s): CRISPR based gene therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Biogen
Deal Size: $415.0 million Upfront Cash: $15.0 million
Deal Type: Collaboration October 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
